Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: rucaparib
Trade Name: Rubraca
Date Designated: 07/31/2012
Orphan Designation: Treatment of ovarian cancer
Orphan Designation Status: Designated/Approved
Clovis Oncology, Inc.
5500 Flatiron Parkway
Suite 100
Boulder, Colorado 80301
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: rucaparib
Trade Name: Rubraca
Marketing Approval Date: 12/19/2016
Approved Labeled Indication: As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies (Indication withdrawn)
Exclusivity End Date: 06/10/2022 
Exclusivity Protected Indication* :  As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies (Indication withdrawn)
2 Generic Name: rucaparib
Trade Name: Rubraca
Marketing Approval Date: 04/06/2018
Approved Labeled Indication: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Exclusivity End Date: 04/06/2025 
Exclusivity Protected Indication* :  For the maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in complete or partial response to platinum-based chemotherapy.
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-